INTRODUCTION
Ligand binding to platelet-membrane GPIIb/IIIa is an obligatory step for the process of platelet aggregation. The complexed form of GPIIb/IIIa functions as a receptor for fibrinogen, von Willebrand factor (vWf) and vitronectin. For example, when platelets are stimulated with ADP, then soluble fibrinogen, vitronectin and vWf bind to the activated GPIIb/IIIa complexes [1, 2] . The fact that only a few molecules of soluble fibrinogen bind to GPIIb/IIIa on resting platelets [3, 4] indicates that the inactive conformer of GPIIb/IIIa is the predominant form on the surface of resting platelets. Cellular agonists such as thrombin or ADP are required to elicit the high-affinity fibrinogen-binding state of GPIIb/IIIa [5] [6] [7] [8] . It was also postulated that certain monoclonal antibodies directed against GPIIb or GPIIIa could lead to conformational changes in GPIIb/IIIa resulting in highaffinity ligand binding [3, 6, 9, 10] .
Two amino acid sequences, Arg-Gly-Asp (RGD) existing in the a-chain and the dodecapeptide sequence His-His-Leu-GlyGly-Ala-Lys-Gln-Ala-Gly-Asp-Val (HHLGGAKQAGDV, residues 400-411) in the C-terminus of the y-chain of fibrinogen, are considered as GPIIb/IIIa-binding domains within fibrinogen [11] [12] [13] [14] . In contrast with macromolecular ligands, small synthetic ligands such as RGDS were demonstrated to bind to inactive GPIIb/IIIa in an agonist-independent manner [15] . Du et al. proposed that ligand-mimetic peptides provoke a change in GPIIb/IIIa, exposing neoepitopes (termed ligand-induced binding sites; LIBS) associated with the acquisition of the highaffinity fibrinogen-binding function [16] . Therefore, the RGD sequence may function as a partial agonist to trigger the highaffinity binding of a ligand rather than functioning as a simple competitive antagonist of GPIIb/IIIa. The precise mechanism that results in conformational changes within GPIlb/IIIa, rendering it competent to bind fibrinogen, remain to be eluci-
dated.
In previous studies we demonstrated that tetrafibricin ( Figure  1 ) was a competitive inhibitor of fibrinogen binding to GPIIb/ monoclonal antibody that preferentially recognizes ligandoccupied GPIIb/IIIa. Exposure of the pl-80 epitope by tetrafibricin was also observed on resting human platelets by flow cytometry. On intact platelets, the conformational changes transformed GPIIb/IIIa into a high-affinity receptor for fibrinogen and triggered subsequent platelet aggregation. Tetrafibricin is the first non-peptidic GPIIb/IIIa antagonist reported that has the capacity to induce conformational changes in GPIIb/IIIa. Illa [17] [18] [19] . We also proved that the anti-aggregatory effect of this compound could be attributed to its GPIIb/IIIa blockage rather than to its interference with other physiological pathways inside platelets. This conclusion was based on the inhibitory effects of this compound on: (1) the fibrinogen binding both to purified GPIIb/IIIa and to stimulated platelets; (2) the agonistindependent aggregation in chymotrypsin-treated platelets; and (3) the release reaction induced by ADP, but is not the same reaction induced by thrombin. Recently, several kinds of GPIIb/IIIa antagonist, including snake venoms containing the RGD sequence [20] , monoclonal antibodies directed to GPlIb/IIIa [21] and synthetic peptidomimetic compounds [22, 23] have been developed as platelet inhibitors. In spite of their potent antiplatelet action, some chemical modifications are required for these peptidic or peptidomimetic inhibitors in order to obtain (1) enough bioavailability, (2) long biological half-life and/or (3) sufficient specificity against other RGD-dependent integrins. Immunogenecity is also a matter of concern. Therefore, the elucidation of the action mechanism of tetrafibricin is of great interest for the rational design of non-peptidic GPIIb/IIIa inhibitors with widespread therapeutic potentials.
In an attempt to distinguish whether tetrafibricin interferes with the fibrinogen-GPIIb/IIIa binding by interacting with the receptor (GPIIb/IIIa) or with the ligand (fibrinogen), we examined whether or not tetrafibricin could induce conformational changes within inactive GPIIb/IIIa, previously reported to be caused by peptides containing the RGD sequence [16, 24] . In the present study we found that tetrafibricin did expose neoepitopes on purified inactive GPIIb/IIIa and on resting platelets. Moreover, on intact platelets, tetrafibricin induced conformational changes in GPIIb/IIIa, transforming it into a high-affinity-binding state for fibrinogen (active conformer) and triggering the subsequent platelet aggregation.
These results suggest strongly that tetrafibricin interacts with Inactive and active GPIlb/lila
The purification of GPIIb/IIIa was performed as described previously [26, 27] . Briefly, the Triton X-100 lysate of human platelets from outdated blood was applied to a concanavalin A affinity chromatography column. Glycoproteins retained by concanavalin A were eluted and then applied to an amino- [30] .
Exposure of LIBS on purffied GPIlb/Ilia
The quantitative assay to examine the expression of the pl-80 epitope on GPIIb/IIIa was performed as described previously [27] . Briefly, the wells of microtitre plates were coated with 2 ,tg/ml of pl-80 (100 ,ul/well) overnight at 4°C in buffer B (150 mM NaCl, 1 occupied by RGDS [25] . By using inactive GPIIb/IIIa and immobilized pl-80, a conformational-specific antibody, the ability of tetrafibricin, RGDS and KQAGDV to expose the pl-80 400 (c) epitope on GPIIb/IIIa was examined on a solid-phase system. As shown in Figure 2 , tetrafibricin increased the binding of Figure 3(a) , human platelets incubated with 100 ,sM tetrafibricin stained brightly with pl-80.
As compared with RGDS, tetrafibricin was at least 10 times more effective in increasing pl-80 binding to platelets, because about 1 mM of RGDS was required to induce comparable binding of pl-80 (Figures 3b and 3c ). The rank of order among antagonists for increasing pl-80 binding to platelets was tetrafibricin > RGDS > KQAGDV, which was consistent with their potency in inducing the pl-80 epitope on purified GPIIb/IIIa as described above. RGES did not induce pl-80 binding even at a concentration of 1 mM (results not shown). These results were also consistent with the fact that tetrafibricin was approx. 30 and 90 times more potent than RGDS and KQAGDV respectively, on the inhibitory effect on 1251-fibrinogen-binding to stimulated platelets (Table 1) . Taken together, these results demonstrate that the conformational changes induced by tetrafibricin occurred not only in purified GPIIb/IIIa but also in GPIIb/IIIa present on resting platelets.
Tetrafibricin activates GPIlb/lila on intact platelets
The above data strongly indicated that tetrafibricin could induce conformational changes in GPIIb/IIIa resulting in the exposure of neoepitopes. As demonstrated previously [16, 35] , the interaction of RGDS with platelet results in an enhanced fibrinogen-binding capacity and in platelet aggregation. We next examined whether tetrafibricin can activate GPIIb/IIIa on intact human platelets. It was demonstrated that when GPIIb/IIIa was activated on intact platelets, it was capable of binding macromolecular ligands such as fibrinogen, this binding triggers subsequent platelet aggregation. In this respect, we employed a system in which platelets were preincubated with a test compound and then fixed with paraformaldehyde to freeze the conformation of GPIIb/IIIa. After fixation, platelets were washed to remove the compounds and fibrinogen was added to induce aggregation. As shown in Figure 4 , platelets pretreated with tetrafibricin aggregated after the addition of fibrinogen without the need for agonist stimulation. This aggregation was specific, because platelets pretreated with RGDS, but not RGES, exhibited similar aggregation. Figure 5 Reversible activation of GPIlb/lila on intact platelets by tetrafibricin or RGDS GFPs [(1.5-3) x 108/ml] were incubated with buffer (A), 100,uM tetrafibricin (B) or 1 mM RGDS (C) for 2 min at 37 OC. After adding 1 mg/ml fibrinogen (triangle), platelets were stimulated with 20,uM ADP (arrow) (a). An aliquot of pretreated platelets were gel-filtered through Sepharose 2B to remove the inhibitor before platelet aggregation was induced (b).
activation of GPIIb/IIIa, whereas, at least 10 times more RGDS () 100 luM) was required to induce a comparable extent of aggregation. Similar to agonist-induced platelet aggregation, the aggregation of tetrafibricin-pretreated platelets was inhibited by agents such as RGDS, HHLGGAKQAGDV (residues 400-411), tetrafibricin or EDTA, indicating that fibrinogen binding to activated GPIIb/IIIa was responsible for this aggregation (Table 3) . Direct activation ofGPIIb/IIIa, not cellular activation, seems to be responsible for the effects of tetrafibricin, because agents that elevate the intracellular level of cyclic AMP (prostaglandins 12 or E1), when added simultaneously with tetrafibricin during the preincubation period, did not alter the effect of tetrafibricin (results not shown). Taken together, tetrafibricin can induce conformational changes on inactive GPIIb/IIIa, rendering it capable to bind fibrinogen and to support platelet aggregation after the addition of fibrinogen.
Tetrafibricin interacts with GPIlb/llia in a reversible manner The foregoing data, by the use of a conformation-specific antibody and intact cells, indicated that tetrafibricin, after occupying GPIIb/IIIa, induced conformational changes in the receptor. Finally, we examined whether or not the interaction between tetrafibricin and GPIIb/IIIa, and the subsequent conformational changes, were reversible. As shown in Figure 5 (a), when platelets were incubated with 100 ,uM tetrafibricin, a condition under which both significant conformational changes in GPIIb/IIIa and complete blockage of fibrinogen binding were observed, no aggregation occurred after the addition of fibrinogen (1 mg/ml) and ADP (20 ,M). However, after the removal of the compound by gel filtration, these pretreated (unfixed) platelets had restored their ability to aggregate ( Figure Sb) . It should be noted that no aggregation was observed after the addition of fibrinogen alone (without agonist stimulation). The above observations suggest that on intact platelets, tetrafibricin interacts with the receptor in a reversible manner and that the conformational changes induced by this compound are also fully reversible.
DISCUSSION
Tetrafibricin is a competitive GPIIb/IIIa antagonist that has recently been discovered in the cultural broth of Streptomyces neyagawaensis NR0557. We have reported that the anti-aggregation activity of tetrafibricin was due to its capacity to block the binding of fibrinogen to GPIIb/IIIa [18, 19] . Recently, there have been various studies reporting on GPIIb/IIIa inhibition by snake-venom proteins containing the RGD sequence [20] , monoclonal antibodies directed to GPIIb/IIIa [21, 36] and synthetic peptidomimetic compounds [22, 23, [37] [38] [39] . Considering that other GPIIb/IIIa antagonists are all derived from or designed based on RGD peptide, and are either peptides or peptidomimetics [36, 40] , the structure of tetrafibricin is unusual in having no RGD-mimicking regions.
The RGD sequence was initially identified as one of the domains in the fibrinogen molecule that is recognized by the GPIIb/IIIa receptor. Actually, competitive and complete inhibition of fibrinogen binding to GPIIb/IIIa could be observed with RGD peptides. Moreover, KYGRGDS has been shown to cross-link preferentially to amino acids 109-172 of GPIIIa [41] . Therefore, RGD-containing peptides or RGD mimetics are considered to bind to GPIIb/IIIa in a competitive manner with the ligand. Recently, Du et al. demonstrated that the binding of RGD peptides to GPIIb/IIIa induced conformational changes in GPIIb/IIIa complexes, transforming it into a high-affinity ligandbinding state [16] . It was suggested that certain RGD mimetics might function as partial agonists as well as competitive binding inhibitors for GPIIb/IIIa. [18] . In contrast, the binding of vWf to GPIb/IX was not inhibited. These data, together with those from the present study, support the concept that tetrafibricin inhibits fibrinogen binding through interaction with the receptor and not with the ligand.
pl-80 is a useful tool to probe conformational changes in GPIIb/IIIa; however, there are different anti-LIBS antibodies with different epitopes on GPIIb/IIIa [24, 31, 42] . Moreover, ligand-induced conformational changes in the GPIIb/IIIa complex have been demonstrated from various approaches, such as susceptibility to proteolytic cleavage, decreases in intrinsic fluorescence and sedimentation coefficient, and increases in stroke radius [43, 44] . We cannot, therefore, draw a simple conclusion that the conformational changes induced by tetrafibricin were exactly the same as those induced by RGDS. Although tetrafibricin does not contain an RGD sequence, it might involve a similar triggering feature. Different approaches, from both biochemical and immunological aspects, will be necessary to address this issue definitively. The IC50 values on LIBS exposure and on 1251-fibrinogen binding for each inhibitorcorrelates well.
These facts might indicate that tetrafibricin, after interacting with GPIIb/IIIa, exposes neoepitopes with similar efficiency to RGDS and y-peptide. The fact that platelets, when preincubated with tetrafibricin before fixation (similar to RGDS-pretreated platelets), exhibited fibrinogen-dependent aggregation without the need for agonist stimulation suggests that this compound is able to convert inactive GPIIb/IIIa into its high-affinity ligandbinding stage. This finding has important functional implications. It suggests that tetrafibricin can function as a partial agonist for GPIIb/IIIa, as well as a competitive binding inhibitor. [45] . Similar to GPIIb/IIIa (zIIb/fla), the initial interaction with the intact ligand, ICAM-1, causes exposure of neoepitopes in leucocyte function-associated antigen-I (LFA-1). Intracellular adhesion molecule-I (ICAM-1) itself can then bind with higher affinity to the altered LFA-1. It is not known at present whether or not non-peptide compounds are able to induce LIBS on other integrin molecules. Since tetrafibricin is the first non-peptide GPIIb/IIIa antagonist reported so far to induce LIBS, it would be interesting to explore the mechanisms of how tetrafibricin induces these conformational changes in GPIIb/IIIa. At present, we could not completely exclude the possibility that GPIIb/IIIa antagonists which induce LIBS lead to a thrombotic episode in physiological situations. However, we now speculate that such a possibility is not so likely, as no agonistic activity has ever been reported in vivo using GPIIb/IIIa antagonists that can induce conformational changes in the receptor [46] . Moreover, our results suggest that, in the suspension of GFPs, the activation of GPIIb/IIIa by tetrafibricin was fully reversible. Of course we admit that the number of in vivo studies is still limited and should be expanded before making final decisions on these issues. Further studies are also required to confirm the reversibility of GPIIb/IIIa activation in physiological situations. The ability of tetrafibricin to induce LIBS and to inhibit platelet aggregation may be a clue for the design of novel GPIIb/IIIa antagonists.
